- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma


Two leadership changes at Lilly

 Eli Lilly has named Sue Mahony its new Senior Vice President and President of its oncology department.

She succeeds John H. Johnson who resigned from his post last month with immediate effect.

John Lechleiter, Lilly Chairman, President and CEO (pictured), says Sue is a “proven leader” and will help maximise the “incredible opportunities” of the company’s clinical-stage pipelines of potential cancer medicines.

Steve Fry has also been promoted to the position vacated by Mahony’s appointment, Senior Vice President of Human Resources, with immediate effect.

Mahony joined Lilly more than a decade ago after working in sales and marketing roles in the UK and Europe in oncology/haematology and cardiovascular medicine for Amgen, Bristol-Myers Squibb, and Schering-Plough.

“Sue brings a deep understanding of both the scientific and commercial aspects of our business gained through a broad range of leadership roles here at Lilly and with other major pharmaceutical companies,” said Lechleiter.

- Advertisement -


- Advertisement -



Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription